Saturday 17 October 2026
Export VIVS’s income statement to Excel — free account
VivoSim Labs, Inc.
VIVS Healthcare Biotechnology
VivoSim Labs, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $131,000.00, down 9.03% from fiscal 2025. In the quarter to June 2026, revenue fell 51.4%, EPS grew 78.1% and free cash flow grew 17.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.16
0.01
−5.88%
Follow VIVS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
4.67 | 0.96 | 0.00 | 0.00 |
P/S ratio |
54.33 | 33.24 | 28.25 | 50.05 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.20) | (2.08) | (1.65) | (1.74) | |
P/B ratio |
1.08 | 1.06 | 0.00 | 0.00 | |
Price to Tangible BV |
1.08 | 1.06 | 0.00 | 0.00 | |
EV/Sales |
6.65 | 3.05 | (10.09) | 35.15 | |
EV/EBITDA |
0.00 | 0.00 | 0.12 | 0.00 | |
EV/Operating CF |
(0.09) | (0.04) | 0.12 | (0.39) | |
EV/FCF |
(0.75) | (0.25) | 0.69 | (3.26) | |
Quick Ratio |
2.74 | 2.15 | 2.18 | 1.43 | |
Current Ratio |
3.10 | 2.44 | 2.38 | 1.70 | |
Net Debt/EBITDA |
2.59 | 1.59 | 1.60 | 0.61 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.03 | 0.01 | 0.01 | |
Operating CF/Net income |
0.93 | 0.84 | 0.39 | 2.40 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.57) | |
Interest Coverage |
— | (687.50) | (796.75) | (689.75) | |
Research and Development Expense of Revenue |
3,296.43% | 4,384.62% | 2,812.50% | 6,288.89% | |
Selling, General and Administrative Expense of Revenue |
6,214.29% | 6,292.31% | 5,255.00% | 9,138.89% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
257.14% | 257.69% | 215.00% | 505.56% | |
Graham Net Nets |
0.65 | 0.75 | (0.50) | (0.53) | |
Graham Number |
6.18 | 8.48 | 7.16 | 6.71 | |
Earnings Yield |
21.43% | 103.69% | (374.83%) | (417.76%) | |
Free Cash Flow Yield |
(16.26%) | (36.16%) | (51.61%) | (21.51%) | |
Revenue per Share |
0.01 | 0.01 | 0.02 | 0.00 | |
Operating CF per Share |
(0.91) | (0.87) | (0.86) | (0.61) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.91) | (0.87) | (0.86) | (0.62) | |
Cash per Share |
2.56 | 1.64 | 1.94 | 0.32 | |
Shareholders Equity per Share |
2.71 | 1.70 | (0.42) | (0.45) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.71 | 1.70 | (0.42) | (0.45) | |
Free Cash Flow |
(2.38) | (2.27) | (2.24) | (3.24) | |
Working Capital |
5.14 | 3.57 | 3.84 | 1.33 | |
Capital Expenditures |
— | — | — | (0.02) | |
Net Current Asset Value |
4.97 | 3.52 | (1.86) | (2.97) | |
EV/EBIT |
0.00 | 0.00 | 0.12 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 1.28 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.03 | 0.54 | 0.54 | 0.54 | |
Average Payables |
0.50 | 0.80 | 1.33 | 0.65 | |
Average Assets |
8.22 | 5.40 | 11.02 | 7.91 | |
Average Common Equity |
5.37 | 2.40 | 4.70 | 3.60 |
Columns are period end dates